Sangui Biotech International, Inc.
SGBI · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | -0.04 | 0.47 | -1.11 |
| FCF Yield | 0.00% | -1.58% | -6.73% | -2.79% |
| EV / EBITDA | 0.00 | -17.63 | -128.17 | -36.41 |
| Quality | ||||
| ROIC | 0.00% | 42.57% | 199.32% | 405.95% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.08 | 2.22 | 0.72 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.45% | 12.36% | 33.75% | -9.33% |
| Free Cash Flow Growth | 0.00% | 91.71% | 3.70% | 14.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -9.25 | -35.35 | -4.78 |
| Interest Coverage | 0.00 | 0.00 | -7.20 | -8.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 107.62 | 70.23 | 138.45 |